FGF-23 and outcomes research - When physiology meets epidemiology

New England Journal of Medicine

Volumn 359, Issue 6, 2008, Pages 640-642

  Hsu, Chi Yuan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; OXYGENASE; PARATHYROID HORMONE; PHOSPHATE;

AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS; BONE STRUCTURE; CHRONIC KIDNEY DISEASE; EDITORIAL; ENZYME ACTIVITY; HUMAN; MINERAL METABOLISM; MORTALITY; ONCOGENIC OSTEOMALACIA; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 49249099354     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0804660     Document Type: Editorial

References (10)

1. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584-92.
2. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16:2205-15.
3. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention and treatment of chronic kidney disease related mineral and bone disorders (CKD-MBD). (Accessed July 18, 2008, at http://www.kdigo.org/clinical-practice-guidelines-1.)
4. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-80.
5. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007;72:1004-13.
6. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
7. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7.
8. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56.
9. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47.
10. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.